About Affymetrix

Stock Quote

Security
AFFX (Common Stock)
$7.37
-1.99%
Current Day's High
7.59
Current Day's Low
7.26
Current Day's Volume
829,500
Last Trade
Apr 23 14 4:00 p.m. ET
Exchange
NASDAQ GS

The stock price performance shown on the quote above is not necessarily indicative of future price performance

Investors

Webcast ImageQ1 2014 Affymetrix Earnings Conference Call
05/01/14 at 5:00 p.m. ET
Webcast -
 Live
Q1 2014 Affymetrix Earnings Conference Call
Thursday, May 1, 2014 5:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Investor Relations Contact

Doug Farrell
VP Investor Relations & Treasury
Tel. 408-731-5285
Fax. 408-731-5750
investor@affymetrix.com

Investor Kit

2014 EBITDAO
2013 EBITDAO
2013 Proxy
2012 Annual Report

Recent News

TitleDate
Affymetrix to Report First Quarter 2014 Operating Results on Thursday May 1st, 2014
SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr. 2, 2014-- Affymetrix, Inc. (NASDAQ: AFFX) today announced that it will report operating results for the first quarter of 2014 after market close on Thursday May 1, 2014. The company will hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the Investor Relations section of the company’s website at www.affymetrix.com. Alternatively, investors and other int... 
04/02/14
Affymetrix Reports Fourth Quarter and Fiscal Year 2013 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb. 5, 2014-- Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the three and twelve months ended December 31, 2013. Results for the three months ended December 31, 2013: Total revenue was $92.6 million, which included revenue from eBioscience of $20.5 million. Product revenue was $82.1 million, as compared to product revenue for the four... 
02/05/14
Affymetrix Receives FDA Clearance of First-of-its-kind Postnatal Test for Developmental Delays and Intellectual Disabilities in Children
CytoScan® Dx Assay represents a technology leap over traditional postnatal genetic tests and significantly improves diagnostic capability SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 21, 2014-- Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan® Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants ... 
01/21/14
University of Bristol Collaborates with Affymetrix on Genotyping Arrays for Guaranteed Sustainability of Wheat Production
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 13, 2014-- Affymetrix, Inc. (NASDAQ: AFFX) and University of Bristol, Bristol, UK, announced today that they have collaboratively designed a wheat genotyping array and analyzed data from experiments as part of an effort to understand wheat genetics and breeding with a goal of ensuring guaranteed sustainable production. Axiom® Wheat Genotyping Array (Axiom Wheat Array), consisting of 817,000... 
01/13/14
— Affymetrix Announces Preliminary Fourth Quarter 2013 Revenue of Approximately $91 Million —
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 7, 2014-- Affymetrix, Inc., (NASDAQ: AFFX) today announced that based on preliminary, unaudited financial data, the Company expects total revenue for the fourth quarter of 2013 will be approximately $91 million, including a one-time licensing payment of $5.3 million from a diagnostic partner. For fiscal 2013, the Company expects total revenue of approximately $329 million. "In 2013 we executed effectively against our three phase strategic plan and we ... 
01/07/14
New Microarray for Identifying and Subtyping Pathogenic E. coli Using Unique DNA Signatures
SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 12, 2013-- Affymetrix, Inc. (NASDAQ: AFFX) announces the availability of a multi-genome pathogen microarray, designed by the Food and Drug Administration's Center for Food Safety and Applied Nutrition (CFSAN) and built by Affymetrix, for the detection and identification of pathogenic E. coli during foodborne outbreaks. These high density DNA-based microarray assays, for use with the GeneAtlas® Personal Microarray System, can detect, discrimina... 
11/12/13
Affymetrix Reports Third Quarter 2013 Operating Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 30, 2013-- Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the third quarter of 2013. Results for the three months ended September 30, 2013: Total revenue was $80.4 million, which included revenue from eBioscience of $19.9 million. Product revenue was $74.8 million, as compared to product revenue for the third quarter of 2012 of $72... 
10/30/13
Affymetrix Axiom® Strawberry Genotyping Array Delivers Automated Analysis for High-Resolution Genome Scanning of Octoploid Strawberry
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 22, 2013-- Affymetrix, Inc. (NASDAQ:AFFX) announces the launch of Axiom Strawberry Genotyping Array (also called International Strawberry 90K SNP array or IStraw90), the only solution that successfully enables high-resolution genotyping and fully automated data analysis of the octoploid strawberry genome. This 90,000 SNP array will enable complex trait research and set the stage for multi-trait, marker-assisted breeding of the cultivated garden strawber... 
10/22/13
Affymetrix to Host Conference Call on October 30th, 2013 to Announce Third Quarter 2013 Operating Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 2, 2013-- Affymetrix, Inc. (NASDAQ: AFFX) today announced that it will report operating results for the third quarter of 2013 after market close on Wed., October 30, 2013. The company will hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the investor relations section of the company's website at www.affymetrix.com. Alternatively, investors and other interested parties may listen to the live conference cal... 
10/02/13
Affymetrix Launches New OncoScan™ FFPE Assay Kit
Breakthrough assay provides genome wide solid tumor copy number analysis in only 48 hours from only 80ng input DNA SANTA CLARA, Calif.--(BUSINESS WIRE)--Aug. 5, 2013-- Affymetrix, Inc. (NASDAQ: AFFX) announced the launch of the new OncoScan™ FFPE Assay Kit, a whole-genome copy number assay for highly degraded FFPE solid tumor samples, at the Cancer Cytogenomics Microarray Consortium conference being held in Chicago this week. De... 
08/05/13
Affymetrix Reports Second Quarter 2013 Operating Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 31, 2013-- Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the second quarter of 2013. Results for the three months ended June 30, 2013: Total revenue was $79.5 million, which included revenue from eBioscience of $18.8 million. Product revenue was $74.2 million, as compared to product revenue on a combined pro forma basis for the se... 
07/31/13
Affymetrix Introduces New Axiom® 384HT Genotyping Format Enabling New Level of Cost-Effective, High-Throughput Genotyping Studies
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 29, 2013-- Affymetrix, Inc. (NASDAQ: AFFX) announces the introduction of the Axiom® 384HT genotyping format, a breakthrough cost-effective, high-throughput format for genotyping in which 384 samples are simultaneously processed with 384 discrete microarrays in a microplate format analyzing up to 50,000 SNPs per sample. The array content of the new Axiom 384HT format is fully customizable, supporting applications ranging from detailed assessment of hum... 
07/29/13
Affymetrix to Announce Second Quarter 2013 Operating Results and Host Conference Call on July 31, 2013
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 8, 2013-- Affymetrix, Inc. (NASDAQ: AFFX) today announced that it will report operating results for the second quarter of 2013 after market close on Weds. July 31, 2013. The company will hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the investor relations section of the company's website at www.affymetrix.com. Alternatively, investors and other interested parties may listen to the live conference call ... 
07/08/13
Affymetrix Appoints Gavin Wood as Executive Vice President and Chief Financial Officer
A seasoned financial leader with extensive international experience SANTA CLARA, Calif.--(BUSINESS WIRE)--May. 20, 2013-- Affymetrix, Inc. (NASDAQ: AFFX) today announced it has appointed Mr. Gavin Wood to the position of Executive Vice President and Chief Financial Officer. Mr. Wood joined Affymetrix in 2006 and served most recently as VP Finance, International Controller based in the United Kingdom. Mr. Wood will report to President and Chief Executive Officer Frank Witney and will oversee ... 
05/20/13
Affymetrix Reports 2013 First Quarter Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr. 30, 2013-- Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the three months ended March 31, 2013. Results for the three months ended March 31, 2013: Total revenue was $77.9 million, which included revenue from eBioscience of $19.0 million. GAAP net loss was $15.4 million, or $0.24 per diluted share, as compared to a net loss of $4.2... 
04/30/13

Receive Email Alerts

Sign up to receive e-mail alerts whenever Affymetrix posts new information to the site. Just enter your e-mail address and click Submit.


Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.


Back to Top >